Experience with International Neuroblastoma Staging System and Pathology Classification (Q36623808)

15 August 2017

Experience with International Neuroblastoma Staging System and Pathology Classification (English)

1 reference

15 August 2017

1 reference

H Ikeda

1

1 reference

15 August 2017

T Iehara

2

1 reference

15 August 2017

Y Tsuchida

3

1 reference

15 August 2017

M Kaneko

4

1 reference

15 August 2017

J Hata

5

1 reference

15 August 2017

H Naito

6

1 reference

15 August 2017

M Iwafuchi

7

1 reference

15 August 2017

N Ohnuma

8

1 reference

15 August 2017

H Mugishima

9

1 reference

15 August 2017

Y Toyoda

10

1 reference

15 August 2017

M Hamazaki

11

1 reference

15 August 2017

J Mimaya

12

1 reference

15 August 2017

S Kondo

13

1 reference

15 August 2017

K Kawa

14

1 reference

15 August 2017

A Okada

15

1 reference

15 August 2017

E Hiyama

16

1 reference

15 August 2017

S Suita

17

1 reference

15 August 2017

H Takamatsu

18

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

86

1 reference

15 August 2017

7

1 reference

15 August 2017

1110-1116

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6600231

15 August 2017

0 references

cites work

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364166

The International Neuroblastoma Pathology Classification (the Shimada system).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364166

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364166

Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364166

A proposed staging for children with neuroblastoma.Children's cancer study group A

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364166

Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364166

Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364166

Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364166

Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364166

Treatment of advanced neuroblastoma with emphasis on intensive induction chemotherapy. A report from the Study Group of Japan.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364166

Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364166

Metastatic neuroblastoma in infancy: what does the pattern of metastases contribute to prognosis?

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364166

Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364166

Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children’s Cancer Group Study

20 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600231

Evaluation of the results of neuroblastoma screening at six months of age

21 January 2018

1 reference

12 December 2020

Long-term survivors of advanced neuroblastoma with MYCN amplification: A report of 19 patients surviving disease-free for more than 66 months

1 reference

12 December 2020

Statistical estimation of prognosis for children with neuroblastoma

1 reference

12 December 2020

Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas

1 reference

12 December 2020

Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study

1 reference

12 December 2020

What is the benefit of aggressive chemotherapy for advanced neuroblastoma with N-myc amplification? A report from the Japanese Study Group for the Treatment of Advanced Neuroblastoma

1 reference

12 December 2020

The Pediatric Oncology Group experience with the international staging system criteria for neuroblastoma. Member Institutions of the Pediatric Oncology Group

1 reference

12 December 2020

Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study

1 reference

12 December 2020

Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas

1 reference

12 December 2020

Additional copies of a 25 Mb chromosomal region originating from 17q23.1-17qter are present in 90% of high-grade neuroblastomas

1 reference

12 December 2020

N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique

1 reference

12 December 2020

Stratification of treatment of stage 4 neuroblastoma patients based on N-myc amplification status. Study Group of Japan for Treatment of Advanced Neuroblastoma, Tokyo, Japan

1 reference

12 December 2020

Clinical investigation of neuroblastoma with partial deletion in the short arm of chromosome 1

1 reference

12 December 2020

Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6600231

1 reference

15 August 2017

1 reference

15 August 2017

1 reference